Blueprint Medicines Corp Live Share Price Today, Share Analysis and Chart

Name: Blueprint Medicines Corp: Is Infosys Ltd. worth buying?
Item: Blueprint Medicines Corp
Rating: 1.819513875
Author: Trendlyne DVM scores

Expensive Rocket

about

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living wit...

129.30 -0.03 (-0.02%)

New 52W High in past week

3.6M

XNAS Volume

XNAS 11 Jul, 2025 5:30 PM (EDT)

Medium Financial Strength

38.9 / 100

Expensive Valuation

6.3 / 100

Technically Moderately Bullish

61.5 / 100

Expensive Rocket These stocks are a favourite among investors due to their bullish nature, good technical aspects but they have bad valuation and medium financials. View Similar Embed DVM

131

1Yr Price target upside is 1%

15 analysts

Blueprint Medicines Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Blueprint Medicines Corp Live Share Price Today, Share Analysis and Chart

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living wit...

New 52W High in past week

SWOT Analysis

Blueprint Medicines Corp Live Price Chart